Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey.
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Cancer Res. 2019 Sep 1;79(17):4339-4347. doi: 10.1158/0008-5472.CAN-19-0214. Epub 2019 Jul 12.
Lung carcinoids (LC) are rare and slow growing primary lung neuroendocrine tumors. We performed targeted exome sequencing, mRNA sequencing, and DNA methylation array analysis on macro-dissected LCs. Recurrent mutations were enriched for genes involved in covalent histone modification/chromatin remodeling (34.5%; , and ) as well as DNA repair (17.2%) pathways. Unsupervised clustering and principle component analysis on gene expression and DNA methylation profiles showed three robust molecular subtypes (LC1, LC2, LC3) with distinct clinical features. gene mutations were found to be exclusively enriched in the LC2 subtype. LC1 and LC3 subtypes were predominately found at peripheral and endobronchial lung, respectively. The LC3 subtype was diagnosed at a younger age than LC1 and LC2 subtypes. IHC staining of two biomarkers, ASCL1 and S100, sufficiently stratified the three subtypes. This molecular classification of LCs into three subtypes may facilitate understanding of their molecular mechanisms and improve diagnosis and clinical management. SIGNIFICANCE: Integrative genomic analysis of lung carcinoids identifies three novel molecular subtypes with distinct clinical features and provides insight into their distinctive molecular signatures of tumorigenesis, diagnosis, and prognosis.
肺类癌(LC)是罕见且生长缓慢的原发性肺神经内分泌肿瘤。我们对宏观解剖的 LC 进行了靶向外显子组测序、mRNA 测序和 DNA 甲基化阵列分析。复发性突变富集了涉及共价组蛋白修饰/染色质重塑(34.5%,包括 和 )以及 DNA 修复(17.2%)途径的基因。基因表达和 DNA 甲基化谱的无监督聚类和主成分分析显示出三个具有明显临床特征的稳健分子亚型(LC1、LC2、LC3)。 基因突变仅在 LC2 亚型中富集。LC1 和 LC3 亚型主要位于外周和支气管内肺。LC3 亚型的诊断年龄比 LC1 和 LC2 亚型年轻。两种生物标志物,ASCL1 和 S100 的 IHC 染色足以对这三种亚型进行分层。LC 分为三个亚型的这种分子分类可能有助于理解它们的分子机制,并改善诊断和临床管理。意义:肺类癌的综合基因组分析确定了三个具有不同临床特征的新型分子亚型,为它们的肿瘤发生、诊断和预后的独特分子特征提供了深入了解。